Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?
NakwonÂ Kwak,Â Margareth PrettiÂ Dalcolmo,Â Charles L.Â Daley,Â GeoffreyÂ Eather,NaokiÂ Hasegawa,Â Won-JungÂ Koh,Â RachelÂ Thomson,Â JakkoÂ van Ingen,Â Jae-JoonÂ Yim
European Respiratory JournalÂ 2019Â 54:Â 1901806;Â DOI:Â 10.1183/13993003.01806-2019
We appreciate the comments from H.Y. Kim and co-workers on our individual patient data meta-analysis onÂ Mycobacterium abscessusÂ pulmonary disease (MAB-PD) . They emphasised the importance of pharmacokinetic (PK)/pharmacodynamic (PD) analysis and therapeutic drug monitoring (TDM) in the field of nontuberculous mycobacterial (NTM) disease, especially for MAB-PD. We generally agree with their perspective.
Pharmacokinetic, pharmacodynamic and therapeutic drug monitoring data are useful in optimising treatment forÂ Mycobacteriuam abscessusÂ pulmonary disease, but such data are not routinely collected and analysis for clinical practice is difficultÂ
Author contributions: The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors, were fully responsible for all content, and were involved at all stages of manuscript development.
Conflict of interest: N. Kwak has nothing to disclose.
Conflict of interest: M.P. Dalcolmo has nothing to disclose.
Conflict of interest: C.L. Daley reports grants from Insmed, and personal fees from Insmed, Johnson & Johnson, Spero, Paratek and Horizon, outside the submitted work.
Conflict of interest: G. Eather has nothing to disclose.
Conflict of interest: N. Hasegawa reports a grant for a clinical trial and personal fees for consultation from Insmed, outside the submitted work.
Conflict of interest: W-J. Koh reports personal fees for advisory boards from Johnson & Johnson and Insmed, outside the submitted work.
Conflict of interest: R. Thomson reports personal fees from Insmed and Savara for advisory boards, and from Menarini for CME talks, outside the submitted work.
Conflict of interest: J. van Ingen reports funding from Insmed, Janssen Pharmaceuticals, Spero Therapeutics and Paratek for advisory boards, during the conduct of the study.
Conflict of interest: J-J. Yim has nothing to disclose.
- ReceivedÂ September 13, 2019.
- AcceptedÂ September 13, 2019.
- Copyright Â©ERS 2019